Reported about 2 months ago
Novo Nordisk's revenue and stock performance have significantly benefitted from Ozempic, a diabetes medication. However, new concerns about potential side effects, particularly an increased risk of suicidal thoughts linked to Ozempic, have surfaced. While some studies suggest these risks may not be as severe as initially reported, the scrutiny surrounding the drug could pose challenges for Novo Nordisk's future sales. Despite this, the company's recent financial results remain strong, indicating resilience amid the concerns.
Source: YAHOO